Frequently Asked Questions
Each answer here is deliberately brief. It states the essentials and then links to the authoritative chapter or appendix, which remains the single source of truth. When the underlying section is updated, the answer here is updated with it.
Questions are grouped by the part of the document their answer draws from, because that source section is what determines when an answer must change. Each question is tagged with the audience(s) it is most relevant to — [Patient], [Carer], [Clinician], [Researcher] — as a navigation aid only.
1 Clinical Presentation
1.1 What is ME/CFS? — [Patient] [Carer] [Clinician]
Myalgic encephalomyelitis / chronic fatigue syndrome is a chronic multisystem disease whose hallmark is post-exertional malaise (PEM): a delayed, disproportionate worsening of symptoms after minor exertion. It is not the same as ordinary tiredness and is not a psychological condition. See Chapter 1 — Introduction and Chapter 3 — Core Symptoms.
1.2 What is post-exertional malaise (PEM)? — [Patient] [Carer] [Clinician]
PEM is the worsening of symptoms after physical, cognitive, or emotional effort that would have been tolerated before illness. It is typically delayed by hours to days and can last days to weeks. It is the feature that most distinguishes ME/CFS from other fatiguing conditions. See Chapter 3 — Core Symptoms.
1.3 How is ME/CFS diagnosed? — [Patient] [Clinician]
There is no single confirmatory test. Diagnosis is clinical, using established criteria (which require PEM), together with exclusion of other conditions that can mimic ME/CFS. See Chapter 5 — Diagnostic Criteria.
1.4 What else should be ruled out first? — [Clinician]
Anaemia, thyroid and other endocrine disease, sleep apnoea, malignancy, and nutritional deficiencies can all mimic ME/CFS and must be excluded before the diagnosis is settled. See Chapter 5 — Differential Diagnosis.
1.5 Does ME/CFS get better or worse over time? — [Patient] [Carer]
The course varies widely between individuals — some improve, some remain stable, some deteriorate. Severity ranges from mild to very severe (housebound or bedbound). See Chapter 6 — Disease Course.
2 Pathophysiology
2.1 What actually causes ME/CFS? — [Patient] [Clinician] [Researcher]
No single cause is established. The evidence points to a multisystem disturbance spanning energy metabolism, immune dysfunction, neurological and autonomic involvement, and endocrine dysregulation, often triggered by infection. See Part II — Pathophysiology.
2.2 Is it an energy-production problem? — [Patient] [Researcher]
Impaired cellular energy metabolism is one of the most consistent findings, though whether it is a root cause or a downstream consequence remains open. See Chapter 7 — Energy Metabolism.
2.3 Is ME/CFS an autoimmune disease? — [Clinician] [Researcher]
Autoimmune mechanisms are plausible for a subset of patients, but the evidence (including GPCR autoantibody findings) is mixed and not yet confirmatory. The largest screens have failed to replicate an ME/CFS-specific autoantibody signal. See Chapter 8 — Immune Dysfunction.
3 Treatment
3.1 Is there a cure? — [Patient] [Carer]
No. No treatment cures ME/CFS. Management aims to reduce symptoms, avoid PEM, and preserve function. See Part III — Treatment.
3.2 What is pacing, and why does it matter? — [Patient] [Carer] [Clinician]
Pacing is staying within your energy limits to avoid triggering PEM. It is the foundation of ME/CFS management. Graded exercise therapy, by contrast, can cause harm and is not recommended. See Chapter [Symptom-Based Management](../part3-treatment/ch23-symptom-management/index.html#ch-symptom-management) — Managing PEM.
3.3 How does low-dose aripiprazole work in ME/CFS? — [Patient] [Clinician] [Researcher]
Aripiprazole is a dopamine D2 partial agonist at all doses; its net effect depends on background dopamine tone rather than switching with dose. In ME/CFS the proposed benefit is dopaminergic and microglial (anti-inflammatory) modulation. The evidence is a single uncontrolled retrospective study, and the mechanism remains speculative; metabolic monitoring and CYP2D6 status matter. See Chapter [Medications Targeting Underlying Mechanisms](../part3-treatment/ch28-medications-systems/index.html#ch-medications-mechanisms) — Atypical Antipsychotics and the Annotated Bibliography — Low-Dose Aripiprazole.
3.4 What should be done for a severely affected, bedbound patient? — [Carer] [Clinician]
Severe ME/CFS needs a fundamentally different, low-stimulation approach with careful attention to nutrition, hydration, and avoidance of exertion. This is urgent. See Chapter [Urgent Action Plan for Severe Cases](../part3-treatment/ch24-urgent-action-severe/index.html#ch-urgent-action-severe) — Urgent Action, Severe.
4 Research
4.1 Are there validated biomarkers? — [Patient] [Clinician] [Researcher]
Not yet. Several candidates are under study, but none is validated for routine diagnostic use. See Chapter 35 — Biomarker Research.
4.2 What treatments are in clinical trials? — [Patient] [Researcher]
Several, spanning antivirals, immunomodulators, and dopaminergic agents, but most evidence remains early-stage or uncontrolled. See Chapter 36 — Clinical Trials.
5 Modeling
5.1 Why does this document include mathematical models? — [Researcher]
Formal models (causal, energetic, immune, neuroendocrine) make hypotheses explicit and testable, and force uncertainty to be stated quantitatively rather than in hand-wavy prose. See Part V — Modeling.
6 About this document
6.1 What is the blue ribbon logo, and what does it mean? — [Patient] [Carer]
The blue ribbon in this site’s logo is the international awareness ribbon for ME/CFS. It is a symbol of support for people affected by the illness, and it is worn and promoted most visibly around May 12, International ME/CFS Awareness Day — the birthday of Florence Nightingale, who is believed to have had an ME/CFS-like illness.
The ribbon is also described as a triple symbol of hope: it raises awareness of ME/CFS, it raises funds for research, and it shows support for those affected.
Its use is associated with the BRAME campaign — “Blue Ribbon for the Awareness of ME” — which was launched in Britain in 1995 and spread internationally. The colour blue is the recognised ME/CFS awareness colour.
Sources: - BRAME — About the Blue Ribbon for the Awareness of ME - MEpedia — Blue Ribbon Awareness for ME - May 12th International Awareness Day — Awareness Ribbons - The ME Association — ME Awareness Week - CDC — ME/CFS Awareness Day - me-gids.net — Blue Ribbon Campaign for ME/CFS
See Patient Resources for actionable aids such as the Hidden Disabilities Sunflower and support-organisation directories.